American Academy of Ophthalmology Meeting
American Academy of Ophthalmology Meeting
November 15, 2019
1 min read
Save

Luminate shows potential in dry AMD

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

SAN FRANCISCO — Luminate showed potential for the treatment of intermediate dry age-related macular degeneration, according to study results presented at Retina Subspecialty Day prior to the American Academy of Ophthalmology annual meeting.

“The pathogenesis of dry AMD is not well established; however, there’s toxicity of stress that causes photoreceptor and RPE-degeneration and incites inflammation – all these lead to a potential loss of function,” David S. Boyer, MD, of the Retina-Vitreous Associates Medical Group, California, said during the presentation. “This drug will block the toxicity of stress, the photoreceptor- and RPE-degeneration and reduce inflammation.”

Boyer and colleagues examined the safety and efficacy of Luminate (risuteganib, Allegro Ophthalmics) for dry AMD in a prospective, double-masked, placebo-controlled, multicenter phase 2 study. The researchers randomly assigned eyes with best corrected visual acuity (BCVA) between 20/40 and 20/200 to receive 1-mg risuteganib or sham at baseline. The risuteganib group received a second dose at week 16, and the sham group could cross over to receive one dose of 1-mg risuteganib.

The researchers measured change in BCVA of the risuteganib group from baseline to week 28 compared with sham from baseline to week 12 (primary endpoint).

Forty-five patients were enrolled in the study (mean age = 76.2 years; 76% women; mean baseline BCVA = 61 letters), according to the abstract.

Boyer reported there was much better vision improvement with risuteganib vs. sham. Compared with sham, more patients who received risuteganib gained 8 or more letters (48% vs. 7%; P = .013).

Additionally, from baseline, the number of patients who gained 10 or more letters was 7.1% with sham vs. 32% with risuteganib and 0% vs. 20%, respectively, gained 15 letters or more, according to the presentation. Further, Boyer reported risuteganib showed good safety profile; no systemic or ocular serious adverse events occurred.

“In conclusion, risuteganib is a small synthetic peptide that regulates select integrin function that, in phase 2, met its primary endpoint,” Boyer said. “We’ve learned that this drug may last a long time. A larger trial is underway.” – by Savannah Demko

Reference: Jaffe GJ, et al. Primary results from phase 2 study of risuteganib in intermediate dry AMD. Presented at: American Academy of Ophthalmology annual meeting; Oct. 11-15, 2019; San Francisco.

Disclosure: Boyer reports consulting for and having equity for Allegro.